A new platform for new promises in hematology  

作　　者：Tao Cheng 

机构地区：[1]Editor-in-Chief,Blood Science,Professor of Medicine and Stem Cell Biology,Director,State Key Laboratory of Experimental Hematology,Scientific Director,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin,China

出　　处：《Blood Science》2019年第1期1-1,共1页血液科学（英文）

摘　　要：Blood system is unique among all the systems and organs in the body.Measurable changes in blood not only reflect blood disorders(including genetic blood diseases,acquired bone marrow failure,and hematological malignancies)but also indicate pathological conditions of many other nonhematological diseases(e.g.,infectious diseases,autoimmune diseases,diabetes,vascular diseases,and solid tumors).Studies on basic,translational,and clinical hematology will certainly improve our current medical practice and bring more cures for blood diseases as well as other relevant diseases.Given the unprecedentedly advancing technologies such as single cell genomics,gene editing,big data science,and drug development,new developments in hematology and related areas are anticipated to rise more rapidly than others.Therefore,there is an urgent need for new publication channels in the field of hematology.This demand is more appealing in Asia because there are very few English hematology journals in Asia.In particular,China has continuingly invested in science and technology since a decade ago and new scientific discoveries are booming as also exemplified in hematology research.However,a continuous growth of scientific discoveries is encountering the space limit and imbalanced distribution of current international journals.As a consequence,many quality papers cannot be published timely.

关 键 词：BLOOD ORGANS CONSEQUENCE 

分 类 号：R55[医药卫生—血液循环系统疾病]